| Brett Lopas, | |
|
1511 S Commercial St, Neenah, WI 54956-4801 | |
| (920) 720-0660 | |
| (920) 720-0666 |
| Full Name | Brett Lopas |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 6 Years |
| Location | 1511 S Commercial St, Neenah, Wisconsin |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215420021 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Schubbe Resch Chiropractic And Physical Therapy Center Llc | 8820031917 | 8 |
News Archive
Good Samaritan Hospital's Stroke Program has attained The Joint Commission's Gold Seal of Approval® and the American Heart Association/American Stroke Association's Heart-Check mark as a certified primary stroke center. The recognition means the Stroke Program has met The Joint Commission's standards for providing stroke care.
The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) - a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
› Verified 2 days ago
| Provider Name | Schubbe Resch Chiropractic & Physical Therapy Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1619156189 PECOS PAC ID: 8820031917 Enrollment ID: O20050609000501 |
News Archive
Good Samaritan Hospital's Stroke Program has attained The Joint Commission's Gold Seal of Approval® and the American Heart Association/American Stroke Association's Heart-Check mark as a certified primary stroke center. The recognition means the Stroke Program has met The Joint Commission's standards for providing stroke care.
The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) - a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
› Verified 2 days ago
| Provider Name | Athletic & Therapeutic Institute Of Milwaukee, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801907464 PECOS PAC ID: 2062469190 Enrollment ID: O20140616000469 |
News Archive
Good Samaritan Hospital's Stroke Program has attained The Joint Commission's Gold Seal of Approval® and the American Heart Association/American Stroke Association's Heart-Check mark as a certified primary stroke center. The recognition means the Stroke Program has met The Joint Commission's standards for providing stroke care.
The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) - a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett Lopas, 1511 S Commercial St, Neenah, WI 54956-4801 Ph: (920) 720-0660 | Brett Lopas, 1511 S Commercial St, Neenah, WI 54956-4801 Ph: (920) 720-0660 |
News Archive
Good Samaritan Hospital's Stroke Program has attained The Joint Commission's Gold Seal of Approval® and the American Heart Association/American Stroke Association's Heart-Check mark as a certified primary stroke center. The recognition means the Stroke Program has met The Joint Commission's standards for providing stroke care.
The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) - a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
› Verified 2 days ago
Elizabeth Bonson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-729-2155 | |
Miss Maria T Joseph, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-725-9373 | |
Christopher T Hupf, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 145 N Commercial St, Neenah, WI 54956 Phone: 920-215-6225 Fax: 920-215-3947 | |
Sarah M Martin, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-454-2973 Fax: 920-720-7350 | |
Rebecca A Van Heuklon, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-729-7665 | |
Mrs. Marni Jeanne Vankeulen, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1516 S Commercial St, Neenah, WI 54956 Phone: 920-729-3350 Fax: 920-720-7276 | |
Alyssa Ann Rotzenberg, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-729-3100 |